Compare HOFT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOFT | MOLN |
|---|---|---|
| Founded | 1924 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 158.9M |
| IPO Year | 1999 | 2021 |
| Metric | HOFT | MOLN |
|---|---|---|
| Price | $13.00 | $4.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 24.2K | 1.8K |
| Earning Date | 03-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $397,465,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.61 | $285.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.34 | $3.36 |
| 52 Week High | $15.99 | $5.36 |
| Indicator | HOFT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.13 | 53.05 |
| Support Level | $9.02 | $3.50 |
| Resistance Level | $13.47 | $5.36 |
| Average True Range (ATR) | 0.69 | 0.18 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 14.08 | 25.34 |
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.